Core Insights - Shanghai Jianda Zhixin Medical Technology Group Co., Ltd. successfully held its IPO listing ceremony on September 25, marking a significant milestone for the company and its stakeholders [1][2]. Company Overview - Jianda Group, a leading state-owned enterprise in Xiamen, focuses on five major sectors: supply chain operations, urban construction and operation, tourism and exhibitions, healthcare, and emerging industry investments, consistently ranking among the "Fortune Global 500" [1]. - Jianda Zhixin has positioned itself as a key player in the medical device supply chain sector, emphasizing the importance of deepening medical reform and ensuring supply chain security [1]. Market Performance - On its first trading day, Jianda Zhixin's stock opened at a remarkable increase of 410.64%, priced at 36 CNY per share, and closed at 36.56 CNY, reflecting a total increase of 418.58% [2]. Strategic Vision - The company aims to leverage its IPO as a catalyst for growth, focusing on addressing industry pain points and enhancing service quality in the healthcare sector [2]. - Jianda Zhixin's mission is to create value through professionalism and provide high-quality services for life and health [2]. Leadership Statements - Key leaders, including the Director of Xiamen State-owned Assets Supervision and Administration Commission and the Chairman of Jianda Zhixin, emphasized the company's commitment to innovation and social responsibility during their speeches at the listing ceremony [2]. - The collaboration with CITIC Securities is expected to enhance Jianda Zhixin's capabilities in industry chain integration and investment services [2].
[新股]建发致新9月25日登陆创业板 开启医疗器械供应链服务新篇章